Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 1/20 | 0.34 |
| ▸ | EDNRB | P24530 | 7/20 | 0.34 |
| ▸ | EDNRA | P25101 | 5/20 | 0.34 |
| ▸ | FABP4 | P15090 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12624289 | 1.00 | HTR2A (0.36) | HTR2AHTR2CHTR2BPTGDR2FFAR4 | |
| SCHEMBL832326 | 0.94 | GPR6 (0.37) | HTR2AHTR2CHTR2BPTGDR2FFAR4 | |
| SCHEMBL3693520 | 0.94 | GPR6 (0.37) | HTR2AHTR2CHTR2BPTGDR2FFAR4 | |
| SCHEMBL3689437 | 0.91 | KMT2A (0.38) | HTR2AHTR2CHTR2BPTGDR2KDM1A | |
| SCHEMBL832839 | 0.91 | KMT2A (0.38) | HTR2AHTR2CHTR2BPTGDR2KDM1A | |
| SCHEMBL832829 | 0.91 | KMT2A (0.38) | HTR2AHTR2CHTR2BPTGDR2KDM1A | |
| SCHEMBL388003 | 0.85 | KMT2A (0.38) | HTR2AHTR2CHTR2BPTGDR2KDM1A | |
| SCHEMBL832012 | 0.85 | KMT2A (0.38) | HTR2AHTR2CHTR2BPTGDR2KDM1A | |
| SCHEMBL832534 | 0.85 | KMT2A (0.38) | HTR2AHTR2CHTR2BPTGDR2KDM1A | |
| SCHEMBL830167 | 0.85 | EDNRB (0.42) | PTGDR2FFAR4EDNRBEDNRATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-05-05 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | IDO1, IDO2, ZC3HAV1 | HTR2A 111/4885HTR2C 89/4885HTR2B 464/4885 |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | HTR2A 24/4885HTR2C 17/4885HTR2B 117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.